A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Journal article
Dayimu A. et al, (2024), Eur J Cancer, 196
Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Journal article
Spiers L. et al, (2023), BMC Cancer, 23
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Journal article
Starkey T. et al, (2023), Sci Rep, 13
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Journal article
Carroll TM. et al, (2023), Cancer Cell, 41, 1222 - 1241.e7
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Journal article
Rasco DW. et al, (2023), Cancer Chemother Pharmacol, 92, 15 - 28
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Journal article
Nicholson BD. et al, (2023), Lancet Oncol
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Journal article
Hamid O. et al, (2023), J Immunother Cancer, 11
Correction: sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
Journal article
Fane ME. et al, (2023), Clin Cancer Res, 29
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.
Journal article
Woodcock VK. et al, (2023), BJUI Compass, 4, 322 - 330
Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells.
Journal article
Jainarayanan A. et al, (2023), iScience, 26
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
Journal article
Larkin J. et al, (2023), Clinical cancer research : an official journal of the American Association for Cancer Research
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)
Supplementary Figure from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Other
Cheng VWT. et al, (2023)